Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

Figure 3

Swimmer’s plot demonstrating duration of treatment and progression-free survival.